Monoclonal and bispecific antibodies as novel therapeutics

被引:31
作者
Booy, EP
Johar, D
Maddika, S
Pirzada, H
Sahib, MM
Gehrke, I
Loewen, S
Louis, SF
Kadkhoda, K
Mowat, M
Los, M
机构
[1] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3T OV9, Canada
[2] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3T 2N2, Canada
[3] Univ Manitoba, Dept Oral Biol, Winnipeg, MB R3T 2N2, Canada
[4] Univ Manitoba, Manitoba Inst Childs Hlth, Winnipeg, MB R3T 2N2, Canada
基金
加拿大健康研究院;
关键词
bexxar; gleevec; imantib; mitumomab; tositumomab; trastuzumab;
D O I
10.1007/s00005-006-0011-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gene amplification, over-expression, and mutation of growth factors, or the receptors themselves, causes increased signaling through receptor kinases, which has been implicated in many human cancers and is associated with poor prognosis. Tumor growth has been shown to be decreased by interrupting this process of extensive growth factor-mediated signaling by directly targeting either the surface receptor or the ligand and thereby preventing cell survival and promoting apoptosis. Monoclonal antibodies have long been eyed as a potential new class of therapeutics targeting cancer and other diseases. Antibody-based therapy initially entered clinical practice when trastuzumab/Herceptin became the first clinically approved drug against an oncogene product as a well-established blocking reagent for tumors with hyperactivity of epidermal growth factor signaling pathways. In the first part of this review we explain basic terms related to the development of antibody-based drugs, give a brief historic perspective of the field, and also touch on topics such as the "humanization of antibodies" or creation of hybrid antibodies. The second part of the review gives an overview of the clinical usage of bispecific antibodies and antibodies "armed" with cytotoxic agents or enzymes. Further within this section, cancer-specific, site-specific, or signaling pathway-specific therapies are discussed in detail. Among other antibody-based therapeutic products, we discuss: Avastin (bevacizumab), CG76030, Theragyn (pemtumomab), daclizumab (Zenapax), TriAb, MDX-210, Herceptin (trastuzumab), panitumumab (ABX-EGF), mastuzimab (EMD-72000), Erbitux (certuximab, IMC225), Panorex (edrecolomab), STI571, CeaVac, Campath (alemtuizumab), Mylotarg (gemtuzumab, ozogamicin), and many others. The end of the review deliberates upon potential problems associated with cancer immunotherapy.
引用
收藏
页码:85 / 101
页数:17
相关论文
共 168 条
[1]  
Abicht A, 2000, CURR OPIN MOL THER, V2, P593
[2]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[3]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[4]   Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy [J].
Barczyk, K ;
Kreuter, M ;
Pryjma, J ;
Booy, EP ;
Maddika, S ;
Ghavami, S ;
Berdel, WE ;
Roth, J ;
Los, M .
INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) :167-173
[5]   Circulating soluble cytochrome c in liver disease as a marker of apoptosis [J].
Ben-Ari, Z ;
Schmilovotz-Weiss, H ;
Belinki, A ;
Pappo, O ;
Sulkes, J ;
Neuman, MG ;
Kaganovsky, E ;
Kfir, B ;
Tur-Kaspa, R ;
Klein, T .
JOURNAL OF INTERNAL MEDICINE, 2003, 254 (02) :168-175
[6]  
Blagosklonny Mikhail V., 2005, P357, DOI 10.1007/0-387-23695-3_17
[7]   Plasma membrane components of adherens junctions (Review) [J].
Blaschuk, OW ;
Rowlands, TM .
MOLECULAR MEMBRANE BIOLOGY, 2002, 19 (02) :75-80
[8]  
Booy Evan P., 2005, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V4, P349, DOI 10.2174/1568014054546254
[9]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[10]  
Bross PF, 2001, CLIN CANCER RES, V7, P1490